12.3.2021 08:06:59 CET | FOM Technologies |
Company Announcement
Company announcement no. 16 – 2021
Copenhagen, the 12th of March 2021
FOM Technologies’ 51% owned subsidiary MLMC Therapeutics has been granted its first process patent using Slot-die coating, thereby paving the future way for FOM Technologies to provide equipment for the development of new ground-breaking manufacturing of medicine.
The 51% owned subsidiary MLMC Therapeutics has been granted a patent method for manufacturing of multilayered microstructures, that could be used for instance for the development and optimized manufacturing of future medicine. CEO of FOM Technologies Michael Stadi explains: “As FOM Technologies core business is not to develop medicine, a separate subsidiary has been established for this purpose, and at the same time bringing external senior pharmaceutical experts into the owner structure of the subsidiary. A separate legal entity (MLMC Therapeutics ApS), provide us with an opportunity to keep focus on Slot-die coating in the parent company (FOM Technologies A/S), while we have created a structure for future development of pharmaceutical manufacturing methods in the subsidiary.
By nature, we try to be conservative and realistic in relation to future commercial projections, but this could potentially be interesting for pharmaceutical companies. We will now spend the next approx. 6 months to finetune the “proof of concept”, before we start initial talks with major pharmaceuticals to discuss a potential co-operation to develop and scale up manufacturing of selected types of medicine using this manufacturing process”.
———-//———-SELSKABSMEDDELELSE
Patent- og Varemærkestyrelsen udsteder patent til FOM Technologies’ 51% ejede datterselskab.
Selskabsmeddelelse nr. 16 – 2021København d. 12. marts 2021
FOM Technologies 51% ejede datterselskab MLMC Therapeutics har netop fået tildelt sit første procespatent, hvor Slot-die coating udgør den grundlæggende teknologi. Dermed er vejen banet for, at FOM Technologies i fremtiden kan levere udstyr til udvikling af banebrydende ny fremstilling af medicin.
Det 51% ejede datterselskab MLMC Therapeutics har netop fået myndighedernes godkendelse på udtagelse af patent til fremstilling af flerlags mikrostrukturer, som f.eks. kan bruges til udvikling og optimeret fremstilling af fremtidig medicin.
CEO for FOM Technologies Michael Stadi udtaler: ”Da FOM Technologies kerneforretning ikke er at udvikle medicin, har vi valgt at oprette et separat datterselskab til dette formål, samtidig med at vi har bragt eksterne senior farmaceutiske eksperter ind i datterselskabets ejerkreds. En separat juridisk enhed (MLMC Therapeutics ApS) giver os en mulighed for at holde fokus på Slot-die coating i moderselskabet (FOM Technologies A / S), samtidig med at vi har skabt en platform for fremtidig udvikling af medicinske fremstillingsmetoder i datterselskabet.
Af natur prøver vi at være konservative og realistiske i forhold til alle fremtidige kommercielle aspekter, men dette kan potentielt være interessant for medicinalfirmaer. Vi vil nu bruge de næste ca. 6 måneder til at finjustere “proof of concept”, inden vi indleder drøftelser med større medicinalvirksomheder for at diskutere et potentielt samarbejde om at udvikle, og opskalere fremstilling af udvalgte typer medicin via denne fremstillingsproces”.
———-///———-CONTACT INFORMATION | KONTAKT INFORMATION:Company | Selskab:FOM Technologies A/SCEO Michael StadiTlf: +45 20 66 60 44E-mail: ms@fomtechnologies.comwww.fomtechnologies.comCertified Advisor | Certified Advisor:Norden CEF ApSJohn NordenTlf: +45 20 72 02 00E-mail: jn@nordencef.dkwww.nordencef.dkCommunication | Kommunikation:Gullev & Co. ApSBoris GullevTlf: +45 31 39 79 99E-mail: borisgullev@gmail.comwww.gullev.co
Contacts
Michael Stadi, CEO, +45 20 66 60 44, ms@fomtechnologies.com
Attachments
Download announcement as PDF.pdf
